Nearly seventeen years after pioneering the production of pharmaceutical products used in nuclear medicine in Morocco, Moroccan firm RIM Pharma is gearing up for a major step forward in its growth.
Currently manufacturing nuclear medicine tracers used in oncology for cancer detection (specifically, Fludeoxyglucose or FDG products), RIM Pharma is now shifting gears with the opening of a new industrial unit at its historic Bouznika site. This new facility will focus on the production of conventional pharmaceutical products, expanding the company’s reach into new therapeutic areas, as the nuclear medicine market remains relatively underdeveloped in Morocco. Despite RIM Pharma’s success in manufacturing FDG, the PET-Scan (Positron Emission Tomography) sessions that use these tracers remain costly, with prices hovering around 8,000 MAD, and coverage for such procedures is still limited.
Spanning nearly 8,000 square meters, the new pharmaceutical unit will be a significant investment, totaling approximately 100 million dirhams, and is expected to be inaugurated in early 2025 after more than two years of construction. The new facility will primarily produce solid dosage forms (tablets, capsules) and focus on high-value therapeutic areas such as cardiology, pulmonology, neurology, and infectious diseases.
In 2023, RIM Pharma reported a revenue of just under 70 million dirhams, with a solid operational margin of over 30%. This performance is largely attributed to the import of conventional pharmaceutical products or their production in partnership with local manufacturers, with plans to manufacture a significant portion of these products in-house once the new plant is operational.
